J2380_LDH-Glo j2381

Simple, More Sensitive LDH Assay Method to Determine Cytotoxicity

  • Detects LDH release from small numbers of cells, including 3D cell models
  • Monitors cytotoxicity from the same sample over time
  • Provides more data per well through multiplexing with other cell-based assays
  • Integrates seamlessly with the MyGlo® Reagent Reader

Catalog Number:

Choose a product

Size

Overview
Protocols
FAQ
Specifications
Related Products
Resources
Citations

少数細胞での細胞毒性モニタリング

LDH-Glo™ Cytotoxicity Assay は細胞膜損傷により培地に放出される乳酸脱水素酵素 (LDH) をプレートベースで発光測定します。発光による測定は発色法や蛍光法に比べて高感度検出を可能にするため、少数の細胞 (初代培養細胞や3D細胞培養を含む)から漏出する LDH でも正確に検出することができます。

このアッセイでは処理後の各ウェルより極少量の培地 (2–5µl) を使用するだけなので、長時間にわたり同じウェル中のサンプルからより多くのデーターを取得できることができ、残った培地や細胞を利用して他の細胞ベースアッセイを行うこともできます。

 

【簡易マニュアル】日本語
※日本語マニュアルは英語版を翻訳したものですが、常に更新されるものではありません。最新のマニュアルについては以下の ”Complete Protocol” をご覧ください。

How Does the LDH-Glo™ Cytotoxicity Assay Work?

アッセイの原理

ダメージを受けた細胞から漏出した LDH は、NAD+ から NADH への還元を伴い乳酸の酸化を触媒します。レダクターゼは NADHと基質を用いてルシフェリンを生成し、これが Ultra-Glo™ rLuciferase により生物発光シグナルに変換されます。
Lactate dehydrogenase detection with LDH-Glo cytotoxicity assay 15079ma-w

How Do I Monitor Cytotoxicity in 3D Cell Cultures?

The LDH-Glo™ Cytotoxicity Assay is well suited for measuring LDH released from small numbers of membrane-damaged cells. Here is an example of measuring drug-induced toxicity in HCT116 spheroids. The time-dependent toxicity measurements were performed by repeatedly sampling media from the same wells.

How do I run the LDH-Glo™ assay with 3D spheroids or organoids, and what controls should I include?

Remove just 2–5µl of medium per timepoint—up to about 10% of a well's starting volume doesn't measurably affect remaining cells or spheroids—dilute into LDH Storage Buffer, and freeze or assay directly. Every plate should include a No-Cell Control (medium background), a Vehicle-Only Control, and, if calculating percent cytotoxicity, a Maximum LDH Release Control using Triton™ X-100.

Because 3D models can have heterogeneous baseline LDH release, normalize to a same-plate, same-treatment-day control rather than comparing raw luminescence values across separate experiments.

Measuring drug-induced toxicity in HCT116 spheroids using the bioluminescent ldh assay 15086mb-wb
HCT116 spheroids were formed using 2,500 cells/well in Corning 384-well Ultra-Low Attachment plates and treated with Doxorubicin. Samples (2.5µl) were collected from the same wells at the indicated time points and frozen in LDH Storage Buffer at a 1:10 dilution. Samples were thawed and further diluted 2.5-fold in LDH Storage Buffer before measuring LDH levels.

How Do I Detect Target Cell Cytotoxicity in ADCC Assays?

ADCC アッセイでのターゲット細胞の細胞毒性検出

LDH-Glo™ Cytotoxicity assay は 補体依存性細胞傷害  (CDC)、抗体依存性細胞媒介性細胞傷害 (ADCC) や抗体-薬物複合体の細胞毒性などバイオロジクス処理の作用機序にともなう様々な細胞死の評価に使用することができます。生物製剤 リツキシマブ を用いたターゲット細胞の ADCC細胞死の検出にLDH-Glo™ Assayを用いた例を示します。
Detection of target cell cytotoxicity in ADCC assays using a bioluminescent ldh assay method 15087mb-wa
Cells were plated at a 20:1 Effector (PBMC):Target (Daudi) ratio and treated with varying concentrations of rituximab (RTX) in triplicate for 4 or 6 hours. Medium samples (2.5µl) from the same wells were removed and diluted into LDH Storage Buffer (47.5µl) and frozen. Twenty-five microliters (25µl) of thawed samples were added to an equal volume of LDH Detection Reagent, and luminescence was recorded after 60 minutes of incubation at room temperature. Concentration of rituximab versus RLU was plotted, and data was fit to 4PL curve to calculate EC50.
Detection of target cell cytotoxicity in ADCC assays using a bioluminescent ldh assay method 15087mb-wb
RLU values from control wells (performed on the same plate as the rituximab treatment) indicate that there is minimal luminescent signal from target or effector cells alone and that addition of rituximab is required for cell killing. ADCC = Effector cells +Target cells + RTX. RLU = Relative Luminescence Units.

Pair with the MyGlo® Reagent Reader

Reading your assay results doesn't require a shared plate reader. The MyGlo® Reagent Reader is a compact 96-well luminescence plate reader, enabling you to run luminescent assays at your bench without competing for instrument time. Integrated software generates dose response curves, single concentration and linearity analysis in minutes.

Learn More about the MyGlo® Instrument
myglo-pp-hero

Frequently Asked Questions

 


 

How can the LDH-Glo™ assay use only 2–5µl of medium for repeated sampling?

Because bioluminescent detection is highly sensitive, only a very small sample is needed to generate a measurable signal. Removing 2–5µl—up to roughly 10% of a well's starting medium volume across several timepoints—doesn't measurably affect the remaining cells, so the same well can be sampled repeatedly to build a time-course without disturbing the culture.

 

What controls are recommended for LDH-Glo™ assay in 3D cultures?

Every assay plate should include a No-Cell Control (triplicate wells without cells, to measure medium background) and a Vehicle-Only Cells Control (untreated cells with the same solvent used for test compounds). If you need percent cytotoxicity, add a Maximum LDH Release Control by treating vehicle-only cells with Triton™ X-100 to lyse them completely before sampling.

 

Can LDH-Glo™ assay samples be frozen and measured later?

Yes. Samples frozen in LDH Storage Buffer show no significant loss of LDH activity after a freeze-thaw cycle, but samples frozen directly in PBS with BSA can lose up to 85% of LDH activity—so always store in LDH Storage Buffer before freezing, not PBS.

 

Can the LDH-Glo™ assay be multiplexed with a cell viability assay?

Yes. Because only a small volume of medium is removed for LDH-Glo™ detection, the remaining sample can be used for RealTime-Glo™ MT, CellTiter-Glo® or CellTiter-Fluor™ viability measurements, or for orthogonal endpoints like Caspase-Glo® 3/7, Glucose-Glo™ or Glutamate-Glo™ assays—helping distinguish cytostatic from cytotoxic effects in the same well.

19869la

 

How do you choose the right sample dilution factor for the LDH-Glo™ assay?

Dilution depends on cell number and whether serum is present, since serum itself contains LDH. Promega's technical manual recommends roughly 5-fold dilution for under 1,000 cells/100µl without serum, up to 100-fold for 10,000–50,000 cells/100µl without serum, and up to 300-fold with 10% serum at higher cell numbers—always confirm results fall within the assay's linear range.

 

Why is bioluminescent LDH detection more sensitive at low signal levels than colorimetric detection?

Bioluminescence produces light against an essentially dark background, so even small amounts of signal are easy to distinguish from noise. Colorimetric detection instead measures a small color change against a comparatively bright background (transmitted light), which requires more analyte to produce a reliably measurable difference—making it less suited to low-cell-number or low-LDH samples.

Specifications

Catalog Number:

選択製品の構成品内容

Item Part # Size

Reductase Substrate

G885A 1 × 55μl

Lactate Dehydrogenase

J195A 1 × 1 each

LDH Detection Enzyme Mix

J238A 1 × 10ml

分析証明書

Search by lot number

使用制限

For Research Use Only. Not for Use in Diagnostic Procedures.

保存条件

AA

パテントおよび免責条項

U.S. Pat. Nos. 9,273,343 and 9,951,372, European Pat. No. 2751089, Japanese Pat. No. 6067019 and other patents pending.

選択製品の構成品内容

Item Part # Size

Reductase Substrate

G885B 1 × 275μl

Lactate Dehydrogenase

J195A 1 × 1 each

LDH Detection Enzyme Mix

J238B 1 × 50ml

分析証明書

Search by lot number

使用制限

For Research Use Only. Not for Use in Diagnostic Procedures.

保存条件

AA

パテントおよび免責条項

U.S. Pat. Nos. 9,273,343 and 9,951,372, European Pat. No. 2751089, Japanese Pat. No. 6067019 and other patents pending.

Product Citations

Recent publications that mention the use of this product.
View PubMed Citations